Trial reportJournal of psychoactive drugs
Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.
Trial report in Journal of psychoactive drugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Pooled it
- Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study.Harm reduction journal · 2025Trial
- Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders.Substance abuse · 2021Trial
- Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder.The American journal on addictions · 2018Trial
- Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months.The American journal of drug and alcohol abuse · 2018Trial
- Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.Journal of addiction medicineTrial
- Targeting Addiction Treatment Engagement: A Canadian Randomized Effectiveness Trial of Remotely Administered Contingency Management for Treatment Attendance: Cibler l'engagement en matière de traitement des dépendances : essai d'efficacité à répartition aléatoire mené au Canada portant sur la gestion des contingences mise en œuvre à distance pour la participation au traitement.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2026Article
- The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal.Addiction biology · 2026Article
- Retention among Medicaid beneficiaries in opioid treatment programs in California.Journal of substance use and addiction treatment · 2026Article
- Heart Rate Variability for Supplementing Withdrawal Assessment in Patients with Opioid Dependence: An Exploratory Study.Indian journal of psychological medicine · 2024Article
- Analyzing quality of life among people with opioid use disorder from the National Institute on Drug Abuse Data Share initiative: implications for decision making.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.EClinicalMedicine · 2023Article
- Quality of life and associated factors of heroin-dependent patients receiving methadone and buprenorphine maintenance treatment.Neuropsychopharmacology reports · 2023Article
- Cessation of self-reported opioid use and impacts on co-occurring health conditions.Drug and alcohol dependence · 2023Article
- Evaluating the Aspects of Quality of Life in Individuals with Substance Use Disorder: A Systematic Review Based on the WHOQOL Questionnaire.Journal of multidisciplinary healthcare · 2023Review
- Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.Substance use & misuse · 2023Article
- A Prospective Three-Months Naturalistic Follow-Up Study of Outcomes of Patients with Opioid Dependence Discharged on Buprenorphine or Oral Naltrexone.Indian journal of psychological medicine · 2023Article
- Comparison of Psychopathologic Characteristics between Individuals Undergoing Methadone Maintenance Treatment, Opioid Dependents, and Control Group.Addiction & health · 2022Article
- Quality of life and its correlated factors among patients with substance use disorders: a systematic review and meta-analysis.Archives of public health = Archives belges de sante publique · 2022Article
- A scoping review of opioid harm reduction interventions for equity-deserving populations.Lancet regional health. Americas · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Studies of substance abuse treatment outcomes that give priority to cessation of all drug use may obscure other tangible benefits of treatment that are important to patients. The aim of this study was to examine the association between changes in quality of life (QoL) and: (1) retention in treatment; and (2) opioid use as measured by self-report and urine testing. Participants were 300 African American men and women starting outpatient buprenorphine treatment. Participants completed assessments at baseline, three and six months consisting of the World Health Organization's Quality of Life brief scale, Addiction Severity Index, and urine testing for opioids. There were statistically significant increases over time across all four QoL domains: physical, psychological, environmental, and social. Self-reported frequency of opioid use was negatively associated with psychological QoL, but opioid urine test results were not significantly associated with any QoL domains. Continued treatment enrollment was significantly associated with higher psychological QoL and environmental QoL. Patients entering buprenorphine treatment experience improvements in QoL, which are amplified for patients who remain in treatment. Point-prevalence opiate urine test results obtained at each assessment were not associated with any of the QoL domains and may not accurately reflect improvements perceived by patients receiving buprenorphine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.